Johnson & Johnson 관리

관리 기준 확인 2/4

Johnson & Johnson CEO는 Joaquin Duato, Jan2022 에 임명되었습니다 의 임기는 2.83 년입니다. 총 연간 보상은 $ 28.40M, 5.6% 로 구성됩니다. 5.6% 급여 및 94.4% 보너스(회사 주식 및 옵션 포함). 는 $ 55.82M 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 55.82M. 경영진과 이사회의 평균 재임 기간은 각각 5 년과 4.9 년입니다.

주요 정보

Joaquin Duato

최고 경영자

US$28.4m

총 보상

CEO 급여 비율	5.6%
CEO 임기	2.8yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Joaquin Duato 의 보수는 Johnson & Johnson 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

보상 대 시장: Joaquin 의 총 보상 ($USD 28.40M )은 US 시장( $USD 12.73M ).

보상과 수익: Joaquin 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Joaquin Duato (61 yo)

2.8yrs

테뉴어

US$28,397,240

보상

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% $ 55.8m
Joseph Wolk	Executive VP & CFO	6.3yrs	US$13.91m	0.0029% $ 10.9m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.6yrs	US$7.50m	0.0047% $ 17.2m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.8yrs	US$11.00m	0.0064% $ 23.7m
John Reed	Executive Vice President of Innovative Medicine	1.6yrs	US$20.65m	0.00061% $ 2.3m
Robert Decker	Controller & Chief Accounting Officer	4.9yrs	데이터 없음	0.00082% $ 3.0m
James Swanson	Executive VP & Chief Information Officer	5yrs	데이터 없음	0.00061% $ 2.3m
Jessica Moore	Vice President of Investor Relations	3yrs	데이터 없음	데이터 없음
Dirk Brinckman	Chief Compliance Officer	no data	데이터 없음	데이터 없음
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.1yrs	데이터 없음	0.00035% $ 1.3m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	데이터 없음	데이터 없음
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.3yrs	데이터 없음	0.0034% $ 12.7m

5.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: JNJ 의 관리팀은 경험 ( 5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% $ 55.8m
Anne Mulcahy	Independent Director	15.8yrs	US$410.00k	0.00034% $ 1.3m
Hubert Joly	Independent Director	4.9yrs	US$320.00k	0.00021% $ 774.8k
Marillyn Hewson	Lead Independent Director	5.6yrs	US$360.00k	0.00012% $ 442.7k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% $ 36.9k
Mark McClellan	Independent Director	11.1yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9.4yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% $ 147.6k
Jennifer Doudna	Independent Director	6.6yrs	US$320.00k	0% $ 0
Eugene Woods	Independent Director	less than a year	US$89.15k	데이터 없음
Mark Weinberger	Independent Director	4.9yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	3.9yrs	US$340.00k	0% $ 0

4.9yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: JNJ 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Johnson & Johnson 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson: Tracking Well Above The Industry

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령